Olanzapine 5 mg is a low-dose tablet of an atypical antipsychotic medication used primarily to treat schizophrenia and bipolar I disorder. It’s also prescribed in combination with other medications for bipolar depression and treatment-resistant depression. The 5 mg strength is commonly used as a starting dose before adjustments are made, and it may also be the maintenance dose for some people.
Approved Uses for Olanzapine
Olanzapine (brand name Zyprexa) is FDA-approved for several psychiatric conditions. The main ones are:
- Schizophrenia in adults and adolescents ages 13 to 17
- Bipolar I disorder (manic or mixed episodes) in adults and adolescents ages 13 to 17, either on its own or alongside mood stabilizers like lithium or valproate
- Bipolar I depression when combined with fluoxetine (an antidepressant), in adults and children ages 10 to 17
- Treatment-resistant depression when combined with fluoxetine, in adults who haven’t responded to at least two different antidepressants at adequate doses
An injectable form also exists for treating acute agitation in people with schizophrenia or bipolar mania, though the 5 mg oral tablet is the form most people encounter.
Why 5 mg Specifically
The 5 mg tablet often serves as the starting point for treatment. In clinical practice, initial doses of 5 mg per day are typical before being increased over the first week based on response and tolerability. For schizophrenia and bipolar mania, many people eventually take higher doses, but some remain on 5 mg if it controls symptoms adequately or if side effects limit dose increases.
Olanzapine reaches its peak level in the blood about 6 hours after you take a dose. It stays active in the body for a long time, with a half-life averaging around 30 hours (ranging from 21 to 54 hours depending on the person). This means a single daily dose is sufficient, and it takes several days for the drug to reach a steady level in your system.
How Olanzapine Works in the Brain
Olanzapine belongs to a class called atypical (or second-generation) antipsychotics. It works by interacting with multiple chemical messenger systems in the brain. Its primary effects come from blocking dopamine receptors and serotonin receptors, two signaling systems closely tied to mood regulation, perception, and thought organization.
What makes it “atypical” rather than a traditional antipsychotic is its selectivity. Olanzapine preferentially targets dopamine pathways involved in psychosis while largely sparing the pathways that control movement. This is why it causes fewer involuntary movement problems (like stiffness or tremors) than older antipsychotics. It also increases dopamine and norepinephrine activity in the prefrontal cortex, the part of the brain responsible for planning, decision-making, and working memory, which may help with the cognitive symptoms of schizophrenia.
Off-Label Uses
Prescribers sometimes use olanzapine for conditions beyond its official approvals. These off-label uses include anxiety disorders, insomnia, nausea and vomiting (particularly related to chemotherapy), eating disorders, and substance use disorders. A small pilot study found olanzapine showed improvement in social anxiety disorder compared to placebo, though evidence for many off-label uses remains limited. Low doses like 2.5 mg or 5 mg are more common for these off-label purposes than the higher doses used in schizophrenia.
Common Side Effects
Weight gain is the most well-known side effect of olanzapine, and it’s significant. In a 12-week study of first-episode schizophrenia patients, roughly 81% gained more than 7% of their starting body weight. People who experienced increased appetite were especially affected: 92% of those with appetite changes gained over 7% of their body weight, compared to 43% of those whose appetite stayed the same. Other commonly reported side effects include drowsiness (about 26% of patients), constipation (13%), abnormal liver function tests (13%), dizziness, and restlessness.
Olanzapine also carries a notable risk of metabolic changes. After 12 weeks of use, researchers observed significant increases in fasting blood sugar, insulin resistance, triglycerides, and cholesterol. Nearly 39% of patients developed dyslipidemia (unhealthy cholesterol levels) after just 12 weeks of treatment. Among atypical antipsychotics, olanzapine is categorized as having the greatest risk of metabolic disturbances.
Metabolic Monitoring While Taking Olanzapine
Because of these metabolic risks, regular monitoring is standard practice. Current guidelines recommend checking your weight, fasting blood sugar, and fasting cholesterol levels before starting olanzapine and again at 12 weeks. After that, weight should be checked roughly every 4 months, while blood sugar and cholesterol levels should be rechecked at least once a year. These aren’t optional extras. Catching metabolic changes early gives you and your prescriber the chance to adjust treatment, add lifestyle changes, or switch medications before problems become entrenched.
Important Safety Information
Olanzapine carries a boxed warning, the FDA’s most serious safety alert, regarding use in elderly patients with dementia-related psychosis. Older adults with dementia who take antipsychotic medications face a 1.6 to 1.7 times higher risk of death compared to those taking a placebo. In clinical trials lasting about 10 weeks, the death rate was approximately 4.5% in treated patients versus 2.6% in the placebo group. Deaths were primarily cardiovascular (heart failure, sudden death) or infectious (pneumonia). Olanzapine is not approved for treating dementia-related psychosis.
Drowsiness is common, particularly when starting treatment or increasing the dose. This can affect your ability to drive or operate machinery, especially in the first few days. The sedating effect often lessens over time as your body adjusts.